DESTIN, Fla. — Cell senescence may represent the “most exciting” development in the potential treatment of osteoporosis, according to Michael R. McClung, MD, of Australian Catholic University and the Oregon Osteoporosis Center.
“The last new therapy we had in our field was romosozumab (Evenity, Amgen) in 2019,” McClung told Healio at the Congress of Clinical Rheumatology East. “There are no drugs currently in phase 2 or 3 clinical trials, but there is some exciting pre-clinical work done on drugs not specifically to target the bone, but drugs that deal with